Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Mirati rapeutics

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Expert Ratings for Mirati Therapeutics

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Mirati Therapeutics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Mirati Therapeutics's (NASDAQ:MRTX) reported sales totaled $709.00 thousand. Despite a 5.63% increase in earnings, the company posted a loss of $188.39 million.

Analyst Ratings for Mirati Therapeutics

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Mirati Therapeutics: Q1 Earnings Insights

Mirati Therapeutics: Q1 Earnings Insights

Mirati Therapeutics (NASDAQ:MRTX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Earnings Preview For Mirati Therapeutics

Earnings Preview For Mirati Therapeutics

Mirati Therapeutics (NASDAQ:MRTX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Mirati Therapeutics will report an earnings per share (EPS) of $-3.49.

Mirati Therapeutics's Return On Capital Employed Overview

Mirati Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Mirati Therapeutics (NASDAQ:MRTX) reported Q4 sales of $299.00 thousand. Earnings fell to a loss of $199.62 million, resulting in a 149.36% decrease from last quarter.

Preview: Mirati Therapeutics's Earnings

Preview: Mirati Therapeutics's Earnings

Mirati Therapeutics (NASDAQ:MRTX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Mirati Therapeutics will report an earnings per share (EPS) of $-3.00.

1

Organisations

Occidental Petroleum

B of A Securities

Evercore ISI Group

Hewlett Packard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play